Item | Treatment | SEM | P value | |||||||
---|---|---|---|---|---|---|---|---|---|---|
CON | SPCb | ESBb | FSBLb | FSBBb | CON vs. SPC | CON vs. ESB | CON vs. FSBL | CON vs. FSBB | ||
BW, kg | ||||||||||
 d 0 | 6.6 | 6.6 | 6.6 | 6.6 | 6.6 | 0.3 | 0.862 | 0.914 | 0.948 | 0.931 |
 d 7 | 7.3 | 7.1 | 7.1 | 6.8 | 7.2 | 0.2 | 0.394 | 0.370 | 0.035 | 0.592 |
 d 20 | 12.0 | 11.3 | 11.5 | 11.0 | 11.6 | 0.4 | 0.177 | 0.389 | 0.050 | 0.414 |
 d 39 | 26.1 | 24.6 | 25.0 | 24.1 | 25.3 | 0.8 | 0.122 | 0.230 | 0.038 | 0.381 |
ADG, g | ||||||||||
 Phase 1 (d 0 to 7) | 95 | 66 | 65 | 26 | 77 | 25 | 0.349 | 0.337 | 0.029 | 0.561 |
 Phase 2 (d 7 to 20) | 363 | 324 | 333 | 322 | 340 | 21 | 0.194 | 0.325 | 0.168 | 0.439 |
 Phase 3 (d 20 to 39) | 744 | 702 | 698 | 691 | 722 | 27 | 0.159 | 0.125 | 0.078 | 0.456 |
 Overall (d 0 to 39) | 500 | 462 | 458 | 449 | 479 | 18 | 0.116 | 0.208 | 0.036 | 0.375 |
ADFI, g | ||||||||||
 Phase 1 (d 0 to 7) | 141 | 116 | 118 | 92 | 131 | 16 | 0.212 | 0.260 | 0.017 | 0.605 |
 Phase 2 (d 7 to 20) | 494 | 438 | 456 | 410 | 463 | 29 | 0.170 | 0.359 | 0.043 | 0.452 |
 Phase 3 (d 20 to 39) | 1036 | 938 | 958 | 966 | 987 | 58 | 0.131 | 0.237 | 0.279 | 0.451 |
 Overall (d 0 to 39) | 695 | 624 | 641 | 624 | 659 | 36 | 0.094 | 0.215 | 0.095 | 0.395 |
G:F | ||||||||||
 Phase 1 (d 0 to 7) | 0.60 | 0.69 | 0.58 | 0.57 | 0.63 | 0.10 | 0.475 | 0.824 | 0.880 | 0.829 |
 Phase 2 (d 7 to 20) | 0.74 | 0.74 | 0.73 | 0.79 | 0.74 | 0.03 | 0.985 | 0.902 | 0.148 | 0.875 |
 Phase 3 (d 20 to 39) | 0.72 | 0.76 | 0.73 | 0.72 | 0.75 | 0.02 | 0.287 | 0.888 | 0.979 | 0.457 |
 Overall (d 0 to 39) | 0.72 | 0.75 | 0.73 | 0.73 | 0.74 | 0.02 | 0.447 | 0.967 | 0.973 | 0.618 |